PT1185274E - Composicoes de farmacos contendo acido (e) - 7- [4-(4-fluorofenil)- 6-isopropil-2-[metil ( metilsulfonil)amino] pirimidin-5-il] (3r,5s) -di-hidroxi-hept-6-enoico e um inibidor, indutor ou substrato da isoenzima p450 3a4 - Google Patents

Composicoes de farmacos contendo acido (e) - 7- [4-(4-fluorofenil)- 6-isopropil-2-[metil ( metilsulfonil)amino] pirimidin-5-il] (3r,5s) -di-hidroxi-hept-6-enoico e um inibidor, indutor ou substrato da isoenzima p450 3a4

Info

Publication number
PT1185274E
PT1185274E PT00901264T PT00901264T PT1185274E PT 1185274 E PT1185274 E PT 1185274E PT 00901264 T PT00901264 T PT 00901264T PT 00901264 T PT00901264 T PT 00901264T PT 1185274 E PT1185274 E PT 1185274E
Authority
PT
Portugal
Prior art keywords
isoenzima
methylsulphonyl
enoic
hept
pyrimidin
Prior art date
Application number
PT00901264T
Other languages
English (en)
Portuguese (pt)
Inventor
Raza Ali
Pears John Stuart
Hutchinson Howard Gerard
Schneck Dennis
Baba Takahiko
Touchi Akira
Yamaguchi Yoshitaka
Original Assignee
Astrazeneca Ab
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1185274(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902593.4A external-priority patent/GB9902593D0/en
Priority claimed from GBGB9921063.5A external-priority patent/GB9921063D0/en
Priority claimed from GBGB9921064.3A external-priority patent/GB9921064D0/en
Application filed by Astrazeneca Ab, Shionogi & Co filed Critical Astrazeneca Ab
Publication of PT1185274E publication Critical patent/PT1185274E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT00901264T 1999-02-06 2000-02-01 Composicoes de farmacos contendo acido (e) - 7- [4-(4-fluorofenil)- 6-isopropil-2-[metil ( metilsulfonil)amino] pirimidin-5-il] (3r,5s) -di-hidroxi-hept-6-enoico e um inibidor, indutor ou substrato da isoenzima p450 3a4 PT1185274E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9902593.4A GB9902593D0 (en) 1999-02-06 1999-02-06 Drug combinations
GBGB9921063.5A GB9921063D0 (en) 1999-09-08 1999-09-08 Therapy
GBGB9921064.3A GB9921064D0 (en) 1999-09-08 1999-09-08 Drug combination

Publications (1)

Publication Number Publication Date
PT1185274E true PT1185274E (pt) 2005-03-31

Family

ID=27269637

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00901264T PT1185274E (pt) 1999-02-06 2000-02-01 Composicoes de farmacos contendo acido (e) - 7- [4-(4-fluorofenil)- 6-isopropil-2-[metil ( metilsulfonil)amino] pirimidin-5-il] (3r,5s) -di-hidroxi-hept-6-enoico e um inibidor, indutor ou substrato da isoenzima p450 3a4

Country Status (28)

Country Link
US (3) US6982157B1 (OSRAM)
EP (1) EP1185274B1 (OSRAM)
JP (2) JP2002536331A (OSRAM)
KR (2) KR20010101790A (OSRAM)
CN (1) CN1165310C (OSRAM)
AR (1) AR029333A1 (OSRAM)
AT (1) ATE282415T1 (OSRAM)
AU (1) AU767304B2 (OSRAM)
BR (1) BR0007999A (OSRAM)
CA (1) CA2358632C (OSRAM)
CZ (1) CZ301296B6 (OSRAM)
DE (1) DE60015965T2 (OSRAM)
EE (1) EE04929B1 (OSRAM)
EG (1) EG23858A (OSRAM)
ES (1) ES2232418T3 (OSRAM)
GB (1) GB0000710D0 (OSRAM)
ID (1) ID30485A (OSRAM)
IL (1) IL144715A0 (OSRAM)
IS (1) IS2337B (OSRAM)
MX (1) MXPA01007905A (OSRAM)
MY (1) MY130606A (OSRAM)
NO (1) NO320745B1 (OSRAM)
NZ (1) NZ512982A (OSRAM)
PL (1) PL198034B1 (OSRAM)
PT (1) PT1185274E (OSRAM)
TR (1) TR200102228T2 (OSRAM)
TW (1) TWI282738B (OSRAM)
WO (1) WO2000045817A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
HU230435B1 (hu) 2001-01-26 2016-06-28 Merck Sharp & Dohme Corp Szubsztituált azetidinon vegyületek alkalmazása szitoszterinémia kezelésére
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CA2460340C (en) 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA05004811A (es) 2002-11-06 2005-07-22 Schering Corp Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
KR20130103818A (ko) 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 피브레이트를 포함하는 고형 제제
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
NZ552389A (en) 2004-08-06 2009-05-31 Transform Pharmaceuticals Inc Statin pharmaceutical compositions and related methods of treatment
WO2007005941A2 (en) 2005-07-05 2007-01-11 President And Fellows Of Harvard College Liver targeted conjugates
US20090093499A1 (en) 2005-12-20 2009-04-09 Lek Pharmaceuticals D.D. Pharmaceutical composition
US20080109252A1 (en) * 2006-11-08 2008-05-08 Lafountain Andrea Predicting patient compliance with medical treatment
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies
EP3807892A1 (en) * 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
MX2022001178A (es) 2019-07-31 2022-02-22 Intas Pharmaceuticals Ltd Composicion farmaceutica que comprende inhibidores de la hmg-coa reductasa y fenofibrato.
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
EP0521417B1 (de) * 1991-07-02 1994-11-23 Joh. A. Benckiser GmbH Zusammenfaltbare Vorratsflasche
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US6576660B1 (en) * 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity

Also Published As

Publication number Publication date
BR0007999A (pt) 2001-11-06
CZ301296B6 (cs) 2010-01-06
AU767304B2 (en) 2003-11-06
JP2002536331A (ja) 2002-10-29
AR029333A1 (es) 2003-06-25
KR20010101790A (ko) 2001-11-14
PL198034B1 (pl) 2008-05-30
EE200100406A (et) 2002-10-15
MY130606A (en) 2007-07-31
KR20060117381A (ko) 2006-11-16
NO20013811D0 (no) 2001-08-03
CA2358632C (en) 2008-10-28
EE04929B1 (et) 2007-12-17
JP2007277267A (ja) 2007-10-25
PL364780A1 (en) 2004-12-13
US20060040969A1 (en) 2006-02-23
EG23858A (en) 2007-11-18
IS2337B (is) 2008-02-15
AU2121800A (en) 2000-08-25
TWI282738B (en) 2007-06-21
DE60015965D1 (de) 2004-12-23
CA2358632A1 (en) 2000-08-10
US20090042911A1 (en) 2009-02-12
WO2000045817A1 (en) 2000-08-10
ID30485A (id) 2001-12-13
MXPA01007905A (es) 2003-06-04
CZ20012844A3 (cs) 2001-11-14
CN1165310C (zh) 2004-09-08
US6982157B1 (en) 2006-01-03
NZ512982A (en) 2003-08-29
IL144715A0 (en) 2002-06-30
TR200102228T2 (tr) 2002-03-21
CN1338936A (zh) 2002-03-06
EP1185274B1 (en) 2004-11-17
HK1041817A1 (en) 2002-07-26
ES2232418T3 (es) 2005-06-01
EP1185274A1 (en) 2002-03-13
DE60015965T2 (de) 2006-01-05
NO320745B1 (no) 2006-01-23
IS6009A (is) 2001-07-17
GB0000710D0 (en) 2000-03-08
NO20013811L (no) 2001-10-02
ATE282415T1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
PT1185274E (pt) Composicoes de farmacos contendo acido (e) - 7- [4-(4-fluorofenil)- 6-isopropil-2-[metil ( metilsulfonil)amino] pirimidin-5-il] (3r,5s) -di-hidroxi-hept-6-enoico e um inibidor, indutor ou substrato da isoenzima p450 3a4
EE200100430A (et) Tert-butüül-(E)-(6-[2-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüülsulfonüül)amino]pürimidiin-5-üül]vinüül](4R,6S)-2,2-dimetüül[1,3]dioksaan-4-üül)atsetaadi valmistamismeetod
DK1897546T3 (da) Kombinerede sammensætninger omfattende (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s]-3,5-dihydroxyhept-6-enoinsyre
IL175086A0 (en) Process for the manufacture of the calcium salt of rosuvastatin (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino]pyrimidin-5-yl] 3r,5s)- 3,5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
ZA200205331B (en) Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid.
IS7661A (is) Process for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase
DE50213202D1 (de) Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
TWI341310B (en) Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
DK1144389T3 (da) Krystallinsk bis(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-ensyre]calciumsalt
HK1048950A1 (zh) 含有一種hmg coa還原酶抑制劑的藥用組合物
DK1362050T3 (da) Pyrimidinderivater til inhibition af celleproliferation
AU2003279025A1 (en) Pyridino and pyrimidino pyrazinones for treatment of anxiety and depression
MY142615A (en) Crystalline form of bis [ (e)-7-4(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6 -enoic acid] calcium salt
DE59905472D1 (de) Verwendung von 2-(n-phenylamino)pyrimidinen als fungizide sowie neue 2-(n-phenylamino)pyrimidine
SI1185274T1 (en) Drug combinations comprising (e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)(3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
HUP0104977A3 (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
DK1185274T3 (da) Lægemiddelkombinationer omfattende (E) - 7 -[4- (4-fluorphenyl) - 6 - isopropyl-2 [methyl(methylsulfonyl)amino ]-pyrimidin-5-yl] (3R,5S) - 3,5-dihydroxyhept-6-ensyre og en inhibitor af, en inducer af eller et substrat for P450 isoenzym 3A4
HK1063430A (en) 6-[2-(phosphonomethoxy)alkoxy]pyrimidine derivatives having antiviral activity